NEXGEL, Inc. (NXGL) stock forecast & analysis
4.01
NasdaqCM · USDDelayed by 15 minutes
Up: +3.86, +2570.7%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.1560
- Previous close
- 0.1500
- Day range
- 0.1510 – 0.2203
- 52-week range
- 0.1510 – 57.00
- Volume (shares)
- 10.50M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 487.38K
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.81
- Market cap
- 1.95M
Market Scanner’s AI analysis of NEXGEL, Inc. (NXGL), updated October 2026: NXGL's BioNX integration ramp-up and leadership transition were key discussion points in recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of NEXGEL, Inc. (NXGL) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
NXGL's BioNX integration ramp-up and leadership transition were key discussion points in recent analyses.
Recent analyses for NXGL covered its Q2 2026 financial results, which showed revenue growth but also noted a slower-than-anticipated ramp-up for the BioNX integration. The company announced an investor update call, a leadership transition, and initiated a strategic review. Technical indicators were unavailable for analysis.
NXGL news & sentiment
Market sentiment was shaped by news of an upcoming investor update call and a leadership transition, alongside the initiation of a strategic review. Social media discussion was not covered in the provided notes.
Fundamentals
NXGL has demonstrated positive year-over-year quarterly revenue growth and significant annual revenue expansion. However, the company is currently unprofitable with negative profit, operating, and net income margins.
Factors discussed — upside
- Positive year-over-year quarterly revenue growth of 27.8%
- Annual revenue growth from $2,048,000 in 2022 to $11,421,000 in 2025
Factors discussed — risks
- Currently unprofitable with negative TTM profit and operating margins
- Negative net income across all reported periods
- Slower-than-anticipated ramp-up for BioNX integration
- Leadership transition initiated
- Financial performance
- Revenue growth
- Profitability
- Strategic review
Summary updated .
Analyses
Recent NXGL.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-12 NXGL.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for NEXGEL, Inc.?
- The company has demonstrated positive year-over-year quarterly revenue growth and significant annual revenue expansion between 2022 and 2025.
- What are the risks for NEXGEL, Inc.?
- NXGL is currently unprofitable, with negative profit and operating margins on a trailing twelve-month basis and negative net income across reported periods. Additionally, the integration of BioNX has experienced a slower-than-anticipated ramp-up, and the company is undergoing a leadership transition.
- Is NEXGEL, Inc. bullish or bearish?
- Recent AI analyses of NEXGEL, Inc. examined factors on both sides. Discussed upside: The company has demonstrated positive year-over-year quarterly revenue growth and significant annual revenue expansion between 2022 and 2025. Discussed risks: NXGL is currently unprofitable, with negative profit and operating margins on a trailing twelve-month basis and negative net income across reported periods. Additionally, the integration of BioNX has experienced a slower-than-anticipated ramp-up, and the company is undergoing a leadership transition. These are descriptive observations, not a recommendation.
- What is the latest sentiment on NEXGEL, Inc.?
- Market sentiment was shaped by news of an upcoming investor update call and a leadership transition, alongside the initiation of a strategic review. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse NEXGEL, Inc.?
- Every analysis of NEXGEL, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for NEXGEL, Inc.?
The company has demonstrated positive year-over-year quarterly revenue growth and significant annual revenue expansion between 2022 and 2025.
What are the risks for NEXGEL, Inc.?
NXGL is currently unprofitable, with negative profit and operating margins on a trailing twelve-month basis and negative net income across reported periods. Additionally, the integration of BioNX has experienced a slower-than-anticipated ramp-up, and the company is undergoing a leadership transition.
Is NEXGEL, Inc. bullish or bearish?
Recent AI analyses of NEXGEL, Inc. examined factors on both sides. Discussed upside: The company has demonstrated positive year-over-year quarterly revenue growth and significant annual revenue expansion between 2022 and 2025. Discussed risks: NXGL is currently unprofitable, with negative profit and operating margins on a trailing twelve-month basis and negative net income across reported periods. Additionally, the integration of BioNX has experienced a slower-than-anticipated ramp-up, and the company is undergoing a leadership transition. These are descriptive observations, not a recommendation.
What is the latest sentiment on NEXGEL, Inc.?
Market sentiment was shaped by news of an upcoming investor update call and a leadership transition, alongside the initiation of a strategic review. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse NEXGEL, Inc.?
Every analysis of NEXGEL, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh NXGL.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.